Prostacyclin in vascular diseases. - Recent insights and future perspectives -.
about
Arachidonic Acid and Cerebral Ischemia Risk: A Systematic Review of Observational StudiesMolecular Analysis of the Prostacyclin Receptor’s Interaction with the PDZ1 Domain of Its Adaptor Protein PDZK1Lipid mediators are critical in resolving inflammation: a review of the emerging roles of eicosanoids in diabetes mellitusProstaglandins and inflammation.The SIRT1 activator SRT1720 reverses vascular endothelial dysfunction, excessive superoxide production, and inflammation with aging in miceEicosanoids, β-cell function, and diabetesInteraction of the human prostacyclin receptor with the PDZ adapter protein PDZK1: role in endothelial cell migration and angiogenesis.The prolactin family hormones regulate vascular tone through NO and prostacyclin production in isolated rat aortic ringsThe roles of peroxidase and phospholipase A2 activities of peroxiredoxin 6 in protecting pulmonary microvascular endothelial cells against peroxidative stress.An anti-inflammatory role for C/EBPδ in human brain pericytes.Cytosolic phospholipase A2 contributes to innate immune defense against Candida albicans lung infectionMolecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn.Treatment strategy for type 2 diabetes from the perspective of systemic vascular protection and insulin resistance.Pulmonary Protection Strategies in Cardiac Surgery: Are We Making Any Progress?Exposure to diesel exhaust upregulates COX-2 expression in ApoE knockout mice.Vascular effects of prostacyclin: does activation of PPARδ play a role?Regulation of the human prostacyclin receptor gene by the cholesterol-responsive SREBP1.An eicosanoid-centric view of atherothrombotic risk factorsA Variant in COX-2 Gene Is Associated with Left Main Coronary Artery Disease and Clinical Outcomes of Coronary Artery Bypass Grafting.Affinin (Spilanthol), Isolated from Heliopsis longipes, Induces Vasodilation via Activation of Gasotransmitters and Prostacyclin Signaling Pathways.A Fermented Whole Grain Prevents Lipopolysaccharides-Induced Dysfunction in Human Endothelial Progenitor Cells.Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke.Positive and negative effects of prostaglandins in Alzheimer's disease.Role of silver nanoparticles (AgNPs) on the cardiovascular system.Fluid shear stress induces upregulation of COX-2 and PGI2 release in endothelial cells via a pathway involving PECAM-1, PI3K, FAK, and p38.Prostacyclin receptor in tumor endothelial cells promotes angiogenesis in an autocrine manner.An experimental model of aortic surgery and the effect of Iloprost on lung injury.CYP8A1 gene polymorphisms and left main coronary artery disease.Pharmacodynamic comparison of LY3023703, a novel microsomal prostaglandin e synthase 1 inhibitor, with celecoxib.Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients.Human retinal endothelial cells and astrocytes cultured on 3-D scaffolds for ocular drug discovery and development.Viability, morphology and function of primary endothelial cells on poly(n-butyl acrylate) networks having elastic moduli comparable to arteries.Uridine Adenosine Tetraphosphate-Induced Coronary Relaxation Is Blunted in Swine With Pressure Overload: A Role for Vasoconstrictor Prostanoids.Prostaglandins in the pathogenesis of kidney diseases.
P2860
Q26801643-C55C00C9-EF14-4F09-BBEF-E64A8D96AC3CQ27676679-DD9E83A8-96D2-4069-B1F8-6F2501E97756Q28080521-D326BB18-D039-4822-93B3-C4EFD23EDAC9Q34179727-A8A183CA-55D5-48EE-B6B7-36CDCA23C4DDQ34726907-96930E59-FDA0-4E68-BCB5-AD5960E52C76Q35129888-64E687CB-7E68-413A-B9B5-BCF34D0974EAQ35133592-3C3B64A0-EB53-4F5C-A16C-53E3BF14342CQ35578519-E7CFEDED-E80A-4F3B-9082-E914E94AB64AQ35679904-06140A61-85B2-4FD3-B279-212B2A36DD04Q35844497-FF972E9B-1F17-48DA-A471-BFA4219E82CEQ36097784-DF60C4E2-14DB-4D0F-A083-3458757E9B85Q36105461-F82A104C-4A8C-40B6-9AB6-B8FBB8D21DCDQ36108506-0911B325-E1E7-4814-8C5F-898A8E3204B5Q36241538-DA4F0440-8C92-4ED5-BBF5-937F75A13945Q36267799-B8C55BFB-43A8-464C-A93F-C0A9B5DEBF6CQ36287741-89197E21-14B2-4980-BB20-E8AFE4C39C99Q36302755-F60DC3FC-CD4C-4259-A578-4C840C8AC46FQ36952174-A067B8F1-979D-4916-A1D8-F16197BA420CQ37618237-01285803-8AA8-4276-9A1D-D10A4098D705Q37631720-977E056A-C99A-4329-8846-2304810BD768Q37721438-43F85E5B-9ACF-4ABE-89C8-0CDABB8D917DQ37995534-77CB30AB-3F21-4901-A833-FB8F6E4EE4CDQ38132922-EEF2F449-E271-4A77-9318-A1757ED9114AQ38301573-83A24AF8-BDCD-4164-B90B-11E78884EEC3Q38724570-563C0B15-80F7-473E-9897-58C1A7B17F96Q39387572-1AE68C80-4A32-44C4-AA61-08014DB476E4Q44038297-57F1E334-D8B5-461A-B812-C74E5EF1F897Q44898958-94A50DC4-E075-40B0-8A0F-9964766CAF6DQ47569669-C1811547-CA6B-4B12-9C09-037D76EF3E4FQ48086607-5B217EC4-8356-4391-B6A3-04C1F471856AQ50040024-84808C9C-C3DB-4316-B9B5-FE64F9EA373EQ52896674-7AC28EC3-FE2E-4900-9690-8B5D05A47A48Q55084123-DB5DACD5-4D5C-4C6A-BF0A-86A66CF4A17CQ55399934-C8944F58-8AD3-4298-99ED-9E7A0D877AD2
P2860
Prostacyclin in vascular diseases. - Recent insights and future perspectives -.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prostacyclin in vascular diseases. - Recent insights and future perspectives -.
@en
Prostacyclin in vascular diseases. - Recent insights and future perspectives -.
@nl
type
label
Prostacyclin in vascular diseases. - Recent insights and future perspectives -.
@en
Prostacyclin in vascular diseases. - Recent insights and future perspectives -.
@nl
prefLabel
Prostacyclin in vascular diseases. - Recent insights and future perspectives -.
@en
Prostacyclin in vascular diseases. - Recent insights and future perspectives -.
@nl
P2093
P356
P1433
P1476
Prostacyclin in vascular diseases. - Recent insights and future perspectives -.
@en
P2093
Fumitaka Ushikubi
Jun-ichi Kawabe
Naoyuki Hasebe
P304
P356
10.1253/CIRCJ.CJ-10-0195
P577
2010-04-15T00:00:00Z